vs
Esperion Therapeutics, Inc.（ESPR）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是Esperion Therapeutics, Inc.的1.2倍（$200.5M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 5.2%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -3.3%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ESPR vs ROG — 直观对比
营收规模更大
ROG
是对方的1.2倍
$168.4M
营收增速更快
ESPR
高出138.5%
5.2%
两年增速更快
ESPR
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $200.5M |
| 净利润 | — | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 2.2% |
| 营收同比 | 143.7% | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $0.32 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $168.4M | $201.5M | ||
| Q3 25 | $87.3M | $216.0M | ||
| Q2 25 | $82.4M | $202.8M | ||
| Q1 25 | $65.0M | $190.5M | ||
| Q4 24 | $69.1M | $192.2M | ||
| Q3 24 | $51.6M | $210.3M | ||
| Q2 24 | $73.8M | $214.2M |
净利润ESPRROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-31.3M | $8.6M | ||
| Q2 25 | $-12.7M | $-73.6M | ||
| Q1 25 | $-40.5M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-29.5M | $10.7M | ||
| Q2 24 | $-61.9M | $8.1M |
毛利率ESPRROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率ESPRROG
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 3.5% | ||
| Q3 25 | -11.4% | 7.3% | ||
| Q2 25 | 8.6% | -33.3% | ||
| Q1 25 | -34.0% | -0.2% | ||
| Q4 24 | -6.4% | -6.6% | ||
| Q3 24 | -31.0% | 6.9% | ||
| Q2 24 | 3.5% | 5.3% |
净利率ESPRROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | -35.9% | 4.0% | ||
| Q2 25 | -15.4% | -36.3% | ||
| Q1 25 | -62.2% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -57.2% | 5.1% | ||
| Q2 24 | -83.9% | 3.8% |
每股收益（稀释后）ESPRROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.32 | $0.20 | ||
| Q3 25 | $-0.16 | $0.48 | ||
| Q2 25 | $-0.06 | $-4.00 | ||
| Q1 25 | $-0.21 | $-0.08 | ||
| Q4 24 | $-0.14 | $-0.04 | ||
| Q3 24 | $-0.15 | $0.58 | ||
| Q2 24 | $-0.33 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.2B |
| 总资产 | $465.9M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $167.9M | $197.0M | ||
| Q3 25 | $92.4M | $167.8M | ||
| Q2 25 | $86.1M | $157.2M | ||
| Q1 25 | $114.6M | $175.6M | ||
| Q4 24 | $144.8M | $159.8M | ||
| Q3 24 | $144.7M | $146.4M | ||
| Q2 24 | $189.3M | $119.9M |
股东权益ESPRROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.2B | ||
| Q1 25 | $-426.2M | $1.3B | ||
| Q4 24 | $-388.7M | $1.3B | ||
| Q3 24 | $-370.2M | $1.3B | ||
| Q2 24 | $-344.2M | $1.3B |
总资产ESPRROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $465.9M | $1.4B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.5B | ||
| Q3 24 | $314.1M | $1.5B | ||
| Q2 24 | $352.3M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流ESPRROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $45.2M | $46.9M | ||
| Q3 25 | $-4.3M | $28.9M | ||
| Q2 25 | $-31.4M | $13.7M | ||
| Q1 25 | $-22.6M | $11.7M | ||
| Q4 24 | $-35.0M | $33.7M | ||
| Q3 24 | $-35.3M | $42.4M | ||
| Q2 24 | $-7.2M | $22.9M |
自由现金流ESPRROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $-35.5M | $25.2M | ||
| Q2 24 | $-7.3M | $8.8M |
自由现金流率ESPRROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | -68.7% | 12.0% | ||
| Q2 24 | -9.9% | 4.1% |
资本支出强度ESPRROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | 0.0% | 8.0% | ||
| Q3 24 | 0.3% | 8.2% | ||
| Q2 24 | 0.1% | 6.6% |
现金转化率ESPRROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
ROG
暂无分部数据
